Search Result

Results for "

INa

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (2) Autophagy (5) Calcium Channel (20) Calmodulin (3) CaMK (2) CRAC Channel (2) Cytochrome P450 (1) Drug Derivative (1) Drug-Linker Conjugates for ADC (1) Estrogen Receptor/ERR (1) HSP (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Insulin Receptor (1) Interleukin Related (1) Isotope-Labeled Compounds (3) MyD88 (1) Na+/Ca2+ Exchanger (2) NF-κB (1) Potassium Channel (9) Reference Standards (3) Small Interfering RNA (siRNA) (3) Sodium Channel (23) Transferrin Receptor (1) TRP Channel (2)
By Research Areas:	Cancer (15) Cardiovascular Disease (22) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0280

Ranolazine 4 Publications Verification CVT 303; RS 43285-003	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-100001

SKF-96365 (hydrochloride) Maximum Cited Publications 27 Publications Verification	TRP Channel CRAC Channel Autophagy CaMK Akt Apoptosis Na+/Ca2+ Exchanger Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
SKF-96365 hydrochloride is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor. SKF-96365 hydrochloride reduces calcium ion influx by inhibiting the activity and expression of TRPC6, STIM1 and Orai1. SKF-96365 hydrochloride inhibits voltage-gated sodium current (cardiac *I_Na/NaV1.5) and slows myocardial conduction. SKF-96365 hydrochloride inhibits phosphorylation/activation of CaMKIIγ* and suppresses the downstream AKT signaling pathway. SKF-96365 hydrochloride induces G₂/M phase cell cycle arrest, apoptosis and cytoprotective autophagy in colorectal cancer cells. SKF-96365 hydrochloride alleviates allergic rhinitis symptoms by reducing inflammatory cytokine levels. SKF-96365 hydrochloride reduces intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage and suppresses apoptosis. SKF-96365 hydrochloride inhibits the growth of colorectal cancer xenografts in nude mice . SKF-96365 hydrochloride is applicable to research related to allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception and hyperalgesia .

HY-110195

Smurf1-IN-A01 3 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others Cancer
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-12593

GS967 5+ Cited Publications	Sodium Channel	Cardiovascular Disease
GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late *I_Na* ) with IC₅₀ values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.

HY-17401

Ranolazine dihydrochloride 4 Publications Verification CVT 303 dihydrochloride; RS 43285	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-148792

Relutrigine PRAX-562	Sodium Channel	Neurological Disease
Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel. Relutrigine potently and preferentially inhibits persistent I_Na induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC₅₀ values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity .

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INa-X 14; Insulin X 14	Insulin Receptor Drug Derivative	Metabolic Disease
Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research .

HY-N6868

Dimethyl lithospermate B dmLSB	Sodium Channel	Cardiovascular Disease
Dimethyl lithospermate B (dmLSB) is a selective Na ⁺ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .

HY-18600A

Azimilide dihydrochloride 2 Publications Verification NE-10064 dihydrochloride	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-108579

UCL 1684 dibromide	Potassium Channel	Cardiovascular Disease
UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of I_Na. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness .

HY-A0236

Aprindine	Sodium Channel Potassium Channel Calcium Channel Calmodulin	Cardiovascular Disease
Aprindine is an Ib-class anti-arrhythmic agent. Aprindine mainly exerts its effect by blocking sodium channels (I_Na), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine can also regulate intracellular calcium ion concentration by inhibiting Na ⁺/Ca ²⁺ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias .

HY-18600

Azimilide 2 Publications Verification NE-10064	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide (NE-10064) is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-125942

SKF-96365 Maximum Cited Publications 27 Publications Verification	CRAC Channel TRP Channel CaMK Akt Apoptosis Autophagy Na+/Ca2+ Exchanger Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
SKF-96365 is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor. SKF-96365 reduces calcium ion influx by inhibiting the activity and expression of TRPC6, STIM1 and Orai1. SKF-96365 inhibits voltage-gated sodium current (cardiac *I_Na/NaV1.5) and slows myocardial conduction. SKF-96365 inhibits phosphorylation/activation of CaMKIIγ* and suppresses the downstream AKT signaling pathway. SKF-96365 induces G₂/M phase cell cycle arrest, apoptosis and cytoprotective autophagy in colorectal cancer cells. SKF-96365 alleviates allergic rhinitis symptoms by reducing inflammatory cytokine levels. SKF-96365 reduces intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage and suppresses apoptosis. SKF-96365 inhibits the growth of colorectal cancer xenografts in nude mice . SKF-96365 is applicable to research related to allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception and hyperalgesia .

HY-163549

APN-PEG5-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
APN-PEG5-VC-PAB-MMAE is a drug-linker conjugate part of INA03 (a transferrin-competitive antibody-drug conjugate against CD71) .

HY-A0236A

Aprindine hydrochloride	Sodium Channel Potassium Channel Calcium Channel Calmodulin	Cardiovascular Disease
Aprindine hydrochloride is an Ib-class anti-arrhythmic agent. Aprindine hydrochloride mainly exerts its effect by blocking sodium channels (I_Na), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine hydrochloride significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine hydrochloride can also regulate intracellular calcium ion concentration by inhibiting Na ⁺/Ca ²⁺ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine hydrochloride can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias .

HY-17401S

Ranolazine-d8 dihydrochloride CVT 303-d8 dihydrochloride; RS 43285-d8	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-B0280S2

Ranolazine-d3	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S1

Ranolazine-d8	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5 CVT 303-d₅; RS 43285-003-d₅	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-17401R

Ranolazine dihydrochloride (Standard) CVT 303 dihydrochloride (Standard); RS 43285 (Standard)	Calcium Channel Sodium Channel Autophagy Reference Standards	Cardiovascular Disease Cancer
Ranolazine (dihydrochloride) (Standard) is the analytical standard of Ranolazine (dihydrochloride). This product is intended for research and analytical applications. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-RS16782

Ina Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ina Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ina gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ina Mouse Pre-designed siRNA Set A Ina Mouse Pre-designed siRNA Set A

HY-RS06802

INA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
INA Human Pre-designed siRNA Set A contains three designed siRNAs for INA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

INA Human Pre-designed siRNA Set A INA Human Pre-designed siRNA Set A

HY-12593R

GS967 (Standard)	Sodium Channel	Cardiovascular Disease
GS967 (Standard) is the analytical standard of GS967. This product is intended for research and analytical applications. GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.

HY-156976A

Sulcardine hydrochloride	Calcium Channel Sodium Channel	Cardiovascular Disease
Sulcardine hydrochloride is a multi-ion channel blocker that can reduce I_Na and I_Ca with IC₅₀ values of 26.9 µM and 69.2 µM, respectively. Sulcardine hydrochloride is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine hydrochloride has anti-arrhythmic effects .

HY-156976

Sulcardine	Calcium Channel Sodium Channel	Cardiovascular Disease
Sulcardine is a multi-ion channel blocker that can reduce I_Na and I_Ca with IC₅₀ values of 26.9 µM and 69.2 µM, respectively. Sulcardine is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine has anti-arrhythmic effects .

HY-111245

AZD-1305	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease Neurological Disease
AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research .

HY-126005

VGSC blocker-1	Sodium Channel	Cancer
VGSC blocker-1 is a potent and small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5). VGSC blocker-1 blocks INa peak currents 34.9% at 1 μM and inhibits cell invasion 0.3% at 1 μM in human breast cancer cell line MDA-MB-231, without affecting the cell viability .

HY-B0280R

Ranolazine (Standard) CVT 303 (Standard); RS 43285-003 (Standard)	Reference Standards Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-144652

IDO1-IN-19	Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450	Cardiovascular Disease Cancer
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC₅₀ of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC₅₀s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .

HY-P992387

INA01	Transferrin Receptor	Cancer
INA01 is an unlabeled human monoclonal antibody targeting CD71/TFRC, which can be used in ELISA, FACS and functional assays. INA01 is promising for leukemia-related research .

HY-18600AS

Azimilide-d8 dihydrochloride NE-10064-d8 dihydrochloride	Isotope-Labeled Compounds Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-RS23222

Ina Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ina Rat Pre-designed siRNA Set A contains three designed siRNAs for Ina gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ina Rat Pre-designed siRNA Set A Ina Rat Pre-designed siRNA Set A

HY-A0236AR

Aprindine hydrochloride (Standard)	Reference Standards Sodium Channel Potassium Channel Calcium Channel Calmodulin	Cardiovascular Disease
Aprindine hydrochloride (Standard) is the analytical reference standard of Aprindine hydrochloride (HY-A0236A). This product is used for research and analytical applications. Aprindine hydrochloride is an Ib-class anti-arrhythmic agent. Aprindine hydrochloride mainly exerts its effect by blocking sodium channels (I_Na), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine hydrochloride significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine hydrochloride can also regulate intracellular calcium ion concentration by inhibiting Na ⁺/Ca ²⁺ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine hydrochloride can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias.

Cat. No.	Product Name	Target	Research Area

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INa-X 14; Insulin X 14	Insulin Receptor Drug Derivative	Metabolic Disease
Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992387

INA01	Transferrin Receptor	Cancer
INA01 is an unlabeled human monoclonal antibody targeting CD71/TFRC, which can be used in ELISA, FACS and functional assays. INA01 is promising for leukemia-related research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6868

Dimethyl lithospermate B dmLSB	Cardiovascular Disease Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields Source Classification	Sodium Channel
Dimethyl lithospermate B (dmLSB) is a selective Na ⁺ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-18600AS

Azimilide-d8 dihydrochloride
Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Azimilide-d8 dihydrochloride

Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Host:	Mouse (2) Rabbit (1)
Reactivity:	Human (3) Rat (1) Mouse (1)
Application:	IHC-P (2) WB (1)
Isotype:	IgG (1) IgG2b (2)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82322

	alpha Internexin Antibody (YA2067) INa; NEF5; Alpha-internexin; Alpha-Inx; 66 kDa neurofilament protein; NF-66; Neurofilament-66; Neurofilament 5	WB	Human, Mouse, Rat
	alpha Internexin Antibody (YA2067) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Internexin.

HY-P88426

	CFI Antibody (YA8110) AHUS3; ARMD13; C3b-INa; C3BINa; FI; IF; KAF	IHC-P	Human
	CFI Antibody (YA8110) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CFI.

HY-P88426A

	CFI Antibody (YA8110)(PBS only) AHUS3; ARMD13; C3b-INa; C3BINa; FI; IF; KAF	IHC-P	Human
	CFI Antibody (YA8110) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CFI.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks